ELUT — Elutia Inc.
NASDAQ · Healthcare · Medical Devices
$0.86
-$0.00 (-0.36%)
Elutia Inc. (ELUT) is a medical devices company listed on NASDAQ. It is led by C. Randal Mills Ph.D., based in 12510 Prosperity Drive, Silver Spring, MD, United States, 20904, with about 51 employees. Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Net income was -$17.4M. ELUT currently screens at market cap $101.1M.
Use this ELUT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ELUT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ELUT SEC filings page. Lician reads the product cache first so this HTML stays unique to Elutia Inc. even when a live quote feed is slow.
About Elutia Inc.
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
ELUT Key Statistics
Market Cap
$101.14M
Volume
16,277
Previous Close
$1.01
Day Range
$1.00 – $1.02
EPS
-$1.86
Revenue
$0.00
Net Income
-$53.95M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
51
ELUT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$53.95M | -$37.66M | -$32.90M | -$24.83M |
| EPS (Diluted) | -$1.86 | -$2.07 | -$2.38 | -$2.38 |
Total Assets
$36.13M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$13.24M
Operating Cash Flow
-$22.66M
Free Cash Flow
$0.00
Elutia Inc. Company Information
- Co-Founder, President, CEO & Director
- C. Randal Mills Ph.D.
- Headquarters
- 12510 Prosperity Drive, Silver Spring, MD, United States, 20904
- Website
- elutia.com
- Phone
- 240 247 1170
- IPO / Founded
- 2023-09-07
- Sector
- Healthcare
- Industry
- Medical Devices